A Clinical Study of YL205 in Patients With Advanced Solid Tumors

Summary

This study is a multicenter, open-label, phase I/II study of YL205 in China to evaluate the safety, tolerability, PK characteristics and preliminary efficacy of YL205 in the following selected patients with advanced solid tumors.

Timeline

Start

2024-06-04

Primary completion

2027-07-31

Completion

2030-07-31

Drugs

Indications